Your browser doesn't support javascript.
loading
mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.
Rotundo, Maria Saveria; Galeano, Teresa; Tassone, Pierfrancesco; Tagliaferri, Pierosandro.
Afiliación
  • Rotundo MS; Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy.
  • Galeano T; Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy.
  • Tassone P; Department of Experimental and Clinical Medicine, Translational Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy.
  • Tagliaferri P; Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia PA, USA.
Oncotarget ; 7(19): 27055-66, 2016 May 10.
Article en En | MEDLINE | ID: mdl-26895472

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Serina-Treonina Quinasas TOR Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Serina-Treonina Quinasas TOR Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Italia